Addex Pharmaceuticals SA raised CHF40 million (US$31.9 million) in a Series C financing to fund Phase II trials of its lead compound, ADX10059, a negative allosteric modulator of metabotropic glutamate receptor 5 (mGluR5), in three different indications. (BioWorld Today) Read More
